Phase 3 clinical study of SYN-2510/IMM2510 in combination with chemotherapy in first-line non-squamous and squamous NSCLC and/or first-line TNBC
Latest Information Update: 18 Sep 2024
Price :
$35 *
At a glance
- Drugs IMM-2510 (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 18 Sep 2024 New trial record